In mammary tumor with BRCA mutation mice from GSE130472 dataset, both senescence signature of groups receiving anti-PD-1 and anti-CTLA4 therapies were lower than those of groups without immunotherapy. This evidence concerns the gene CTLA4 and breast cancer.